Treasury proposed adding biotech to US outbound investment rules on October 22, 2026, six days after China moved to wall off its own biotech platforms.
Last updated: October 23, 2026
On October 22, 2026 the US Treasury proposed adding biotechnology to its outbound investment security program, the FDA granted Ultomiris accelerated approval in IgA nephropathy, and Biohaven said its resubmitted spinocerebellar ataxia application was accepted for review.
This page covers the Treasury outbound investment proposal, the Ultomiris IgA nephropathy approval, the Biohaven troriluzole acceptance, QIAGEN’s first session after the EQT offer, and the day’s other regulatory, financing and market moves.
What did the US Treasury propose for biotech investment on October 22, 2026?
Treasury issued a notice of proposed rulemaking that updates the Outbound Investment Security Program and, for the first time, adds biotechnology to the technologies it covers. The release states plainly: “the Secretary has added biotechnology to the proposed regulations.”
The proposal implements the Comprehensive Outbound Investment Security (COINS) Act, which Congress passed as part of the fiscal year 2026 National Defense Authorization Act. The statute directs Treasury to build a two tier structure: US persons must notify Treasury of certain transactions with covered foreign persons engaged in “notifiable technologies,” and certain transactions involving “prohibited technologies” are banned outright. The statute names five sectors, semiconductors and microelectronics, artificial intelligence systems, quantum information technologies, high performance computing, and hypersonic systems, and gives the Secretary authority to add more after notice and comment. Biotechnology is the addition. Treasury Secretary Scott Bessent and Assistant Secretary for Investment Security Christopher Pilkerton announced the proposal.
What the release does not say matters as much as what it does. It does not state which tier biotechnology falls into, prohibited or notifiable. It does not define biotechnology, set dollar thresholds, or give a comment deadline beyond pointing to the official notice on regulations.gov. The effective date waits for a later final rule. The release also never names China; it speaks of “foreign adversaries” and “a country of concern.” The China framing comes from coverage: Bloomberg headlined the proposal as curbs on investment in Chinese biotech firms, and STAT News reported the rule as aimed at the Chinese biotech sector. The NPRM’s technical specifications, including the biotechnology scope, sit in the notice itself, which will be the document worth reading when the details matter to a portfolio or a pipeline.
How does Washington’s proposal compare with China’s biotech export controls?
Within one week, both governments proposed walls around biotech ownership while leaving licensing untouched or unresolved. China’s commerce ministry moved October 16 to block foreign acquisition of its platform technologies. Treasury moved October 22 to restrict the US capital that funds those platforms.
| China: draft export control catalogue (Oct 16) | US: Treasury proposed rule (Oct 22) | |
|---|---|---|
| Instrument | MOFCOM draft update to the export control catalogue (reported by Fierce Biotech; the draft text itself remains unfetched by us) | Notice of proposed rulemaking under the COINS Act, updating the Outbound Investment Security Program (Treasury release, primary) |
| What closes | Bans foreign acquisition of proprietary platforms in cell and gene therapy, siRNA, and pathogen gain of function research; restricts full transfers of target discovery technology | Adds biotechnology to a program that notifies or prohibits US investment in covered foreign persons; which tier biotech lands in is not yet stated |
| What stays open | Out licensing and outsourced research and manufacturing services are excluded; out licensing of target discovery technology “will generally be approved” | The release names no exemptions; excepted transactions are defined in the notice itself |
| Comments | Close November 15, 2026 | Deadline set in the official notice on regulations.gov; not stated in the release |
| Status | Draft; final catalogue pending | Proposed rule; a later final rule sets the effective date |
The symmetry is the story. China’s draft, as reported, protects the engine and sells the output: platforms stay home, molecules remain licensable. The US proposal reaches the other side of the same transaction, the American capital and equity participation that has funded Chinese platform companies. Cross border licensing, the structure behind roughly $120 billion in foreign transactions involving Chinese biotech assets as of August 2026 per figures reported by Fierce Biotech, is the one lane neither proposal has yet closed.
What did the FDA approve Ultomiris for in IgA nephropathy?
AstraZeneca’s Alexion unit announced October 22 that the FDA granted accelerated approval for Ultomiris (ravulizumab) to reduce proteinuria in adults with primary immunoglobulin A nephropathy who are at risk of disease progression. It is the first C5 complement inhibitor approved for this use in the US, by the company’s description, and the fifth Ultomiris indication.
The approval rests on proteinuria, not kidney function. The release is explicit that whether Ultomiris slows the decline in kidney function in people with IgAN has not been established, and that continued approval may depend on the final analysis of the ongoing Phase 3 I CAN study, which measures the change in estimated glomerular filtration rate at week 106. That final readout is intended to support traditional approval.
I CAN (NCT06291376) is a global Phase 3 trial designed to enroll approximately 510 participants in 28 countries, randomized one to one to Ultomiris or placebo on top of stable standard of care. The prespecified interim analysis at week 34 produced the numbers below.
| I CAN interim result (week 34, 24 hour UPCR) | Ultomiris | Placebo |
|---|---|---|
| Reduction in proteinuria from baseline | 46.6% (95% CI 39.0 to 53.2) | 5.6% (95% CI −4.9 to 15.0) |
| Placebo adjusted reduction | 43.4% (95% CI 33.5 to 51.8; p<0.0001) | |
| Reduction at week 10 | 36.7% | 8.5% |
| Most frequent adverse events | Upper respiratory tract infection 11.3%, nasopharyngitis 9.2%, infusion related reactions 8.4% | Upper respiratory tract infection 10.2%, nasopharyngitis 9.0%, hypertension 6.6% |
The company reported interim safety in line with the established Ultomiris profile, with no new safety issues identified. Ultomiris is dosed intravenously every eight weeks after a loading dose. IgAN affects more than 200,000 people in the US by the company’s estimate, and roughly half of those with elevated urinary protein or reduced kidney function face a high risk of kidney failure within ten years of diagnosis. Late breaking I CAN results are scheduled at ASN Kidney Week in Denver on October 23 (Lafayette et al., abstract FR-OR107). AstraZeneca’s US shares closed up 2.4% at 172.57.
How crowded is the IgA nephropathy market now?
Crowded, and about to get more so. Ultomiris enters a field that already includes two targeted therapies with US approvals, and the next decision lands November 30.
| Therapy | Company | Mechanism | US status in IgAN |
|---|---|---|---|
| Filspari (sparsentan) | Travere Therapeutics | Dual endothelin and angiotensin receptor antagonist | Approved |
| Fabhalta (iptacopan) | Novartis | Factor B inhibitor (alternative complement pathway) | Approved |
| Ultomiris (ravulizumab) | AstraZeneca (Alexion) | C5 complement inhibitor | Accelerated approval, October 2026 |
| Povetacicept | Vertex Pharmaceuticals | Dual BAFF and APRIL inhibitor | PDUFA target date November 30, 2026 |
The market read the approval as additive rather than zero sum. Vertex closed up 2.0% at 535.17 ahead of its own November 30 decision, and Travere closed essentially flat, down 0.3% at 52.43. The mechanisms differ enough, and the treated population is large enough, that the field is behaving like a category being built rather than a share fight, at least until label language and payer responses sort the sequencing.
What happened with Biohaven’s troriluzole application?
Biohaven disclosed in a securities filing on October 22, reported by BioPharma Dive, that the FDA accepted its resubmitted new drug application for troriluzole, branded Vyglxia, in spinocerebellar ataxia. The agency plans to convene an advisory committee, and Biohaven expects a decision in the first quarter of 2027.
The resubmission follows a complete response letter in November 2025, in which the FDA found the key supporting analysis unconvincing in part because of its design, per BioPharma Dive’s earlier reporting. Biohaven’s filing says the application returned with “new positive supportive analyses”; the filing language, as quoted, does not specify what they are. No advisory committee date has been announced, and nothing in the October disclosure states that the resubmission carries priority review. The priority review language that circulates with this program dates to the original February 2025 acceptance, a different review cycle.
| Date | Event |
|---|---|
| February 2025 | FDA accepts the original Vyglxia NDA with priority review; decision then expected in the third quarter of 2025 (company release) |
| November 2025 | Complete response letter; FDA questions the design of the key supporting analysis (per BioPharma Dive) |
| October 22, 2026 | FDA accepts the resubmitted NDA with “new positive supportive analyses”; advisory committee planned; decision expected Q1 2027 per Biohaven (securities filing, via BioPharma Dive) |
Spinocerebellar ataxia has no FDA approved treatment. Biohaven shares closed up 25.0% at 14.69, our arithmetic from settled closes. TD Cowen’s Tyler Van Buren told BioPharma Dive that the scheduling of an advisory committee substantially increases the probability of approval; RBC’s Leonid Timashev countered that the odds depend largely on how extensive the agency’s flexibility changes have been. Both readings agree on the mechanism: this is a review restarted under a different regulatory posture toward rare disease evidence.
How did QIAGEN trade after the EQT take private offer?
Quietly. QIAGEN’s New York listed shares closed at 50.22, up 0.4%, in the first full session after EQT and its co investors announced the €46.50 per share all cash offer on Wednesday evening. There was no arbitrage discount blowout and no competing bid speculation visible in Thursday’s coverage.
The offer values QIAGEN at roughly €10.8 billion in enterprise value, a 40.3% premium to the July 8 undisturbed price, with a minimum acceptance threshold of 50% plus one share and an expected close in mid 2027. An orderly first session at this stage reads as the market treating the deal as likely to complete on its terms. The next hard documents are the formal Offer Document and the boards’ reasoned statement, and QIAGEN’s full third quarter results on November 4, which the company will release without a call after suspending its full year outlook.
What other life sciences news crossed on October 22?
Zai Lab priced a $250 million private placement after the close. The company agreed to sell 11,340,000 American depositary shares at $22.04 each, approximately $250 million gross, to a group led by TCGX that includes RA Capital, RTW, Wellington, Frazier, Cormorant, Balyasny, abrdn’s healthcare fund, ADAR1, Sirenia and Woodline. Proceeds go primarily to the global development of zocilurtatug pelitecan, Zai Lab’s DLL3 targeting antibody drug conjugate. The placement is set to close on or about October 27. The $22.04 placement price equals Thursday’s settled close, which arrived after a session in which the ADSs fell 8.9% with no company disclosure during market hours.
Medicare started paying for Lucid Diagnostics’ EsoGuard. Lucid said it has begun receiving Medicare payments for its EsoGuard esophageal DNA test at the established clinical laboratory fee schedule rate of $1,938.01 per test under PLA code 0114U, on claims submitted after its September 22 announcement. The company also closed a $15.0 million Series C convertible preferred private placement on October 21 with existing holders, including a majority of its 12.0% senior secured convertible noteholders, who acknowledged that the Medicare payments resolved the concern behind the notes’ Medicare related default provision.
Labcorp, Charles River and the FDA will work on abuse potential testing together. The three announced a research collaboration to advance the science used to evaluate a medicine’s abuse potential, built on a harmonized behavioral economics methodology to quantify and rank abuse liability. FDA scientists will conduct data analysis and contribute regulatory science expertise; Labcorp brings its regulatory abuse potential study experience. No funding figures or timeline were disclosed.
Mineralys put new lorundrostat kidney data on the board ahead of its December decision. In a Launch-HTN analysis presented at ASN Kidney Week, lorundrostat cut systolic blood pressure by a placebo adjusted 9.6 mmHg at week 12 in participants with chronic kidney disease stages 1 to 3 and 12.2 mmHg in those without, and reduced urine albumin to creatinine ratio by 52.2% versus placebo in CKD participants with baseline albuminuria. Confirmed hyperkalemia was 2.4% in the CKD group. The company’s release states the FDA review has a PDUFA target date of December 22, 2026.
Menarini’s Stemline licensed a preclinical immunotherapy from Georgiamune. Per Fierce Biotech, Stemline paid $45 million upfront for exclusive worldwide rights to GIM-621, described in the companies’ release as a first in class oral small molecule immunotherapy for multiple solid tumors, in a deal worth up to $1.1 billion. Separately, Fierce reported that the rebranded NodThera plans an IPO to fund its NLRP3 inhibitor program, and Roche’s CEO said the company has “absolutely not” changed its view on the $1.5 billion Poseida acquisition despite scrapping one of its assets.
Which stocks moved on October 22, and why?
Settled exchange closes; percentages are our arithmetic against Wednesday’s closes.
| Ticker | Close | Move | Context |
|---|---|---|---|
| BHVN | 14.69 | +25.0% | FDA accepted the resubmitted Vyglxia NDA; advisory committee planned, decision expected Q1 2027 per Biohaven |
| AZN | 172.57 | +2.4% | Ultomiris accelerated approval in IgA nephropathy, the product’s fifth indication |
| IAM | 14.67 | −7.2% | Now 8.3% below the $16.00 IPO offer price, our arithmetic; the debut premium has fully unwound in under two weeks |
| ZLAB | 22.04 | −8.9% | Fell through the session with no disclosure during market hours; the $250 million placement priced at this close after hours |
| QGEN | 50.22 | +0.4% | First full session after the EQT €46.50 take private offer; orderly trade, no spread drama |
| XBI / SPY | 151.64 / 763.96 | −0.7% / −1.2% | Sector held up better than the broad tape on a down day |
Frequently asked questions
What is the Outbound Investment Security Program?
It is the Treasury run program that screens US investment flowing into sensitive technologies in countries of concern. The October 22, 2026 proposed rule updates it under the COINS Act and adds biotechnology to the covered technology list for the first time.
Does the Treasury proposal name China?
No. The release refers to foreign adversaries and a country of concern without naming any state. Coverage from Bloomberg and STAT News frames the proposal as aimed at Chinese biotech, consistent with the program’s existing focus.
Which transactions would be prohibited under the new biotech rules?
Not yet public in the release. The statute creates two tiers, notifiable transactions that require telling Treasury and prohibited transactions that are banned, and the release does not state which tier biotechnology falls into. The notice on regulations.gov carries the technical specifications.
When do comments close on the Treasury proposal?
The release does not give a date; it directs commenters to the deadline in the official notice of proposed rulemaking on regulations.gov. By comparison, comments on China’s draft biotech export control catalogue close November 15, 2026.
What is Ultomiris now approved for in IgA nephropathy?
Accelerated approval to reduce proteinuria in adults with primary IgA nephropathy who are at risk of disease progression. Whether it slows the decline in kidney function has not been established; that question rides on the I CAN final analysis at week 106.
Is the Ultomiris IgAN approval a full approval?
No. It is an accelerated approval based on proteinuria reduction, a surrogate endpoint. Continued approval may depend on verification of clinical benefit in the ongoing I CAN study, whose week 106 kidney function results are intended to support traditional approval.
How much did Ultomiris reduce proteinuria in the I CAN trial?
At the prespecified week 34 interim analysis, 24 hour UPCR fell 46.6% from baseline on Ultomiris versus 5.6% on placebo, a placebo adjusted reduction of 43.4% (95% CI 33.5 to 51.8; p<0.0001), per AstraZeneca’s release.
What other drugs are approved for IgA nephropathy in the US?
Travere’s Filspari (sparsentan) and Novartis’ Fabhalta (iptacopan) are approved, and Ultomiris joins them with an accelerated approval. Vertex’s povetacicept has a PDUFA target date of November 30, 2026.
What is Vyglxia (troriluzole)?
Biohaven’s oral glutamate modulator for spinocerebellar ataxia, a neurodegenerative disease with no FDA approved treatment. The FDA rejected the original application in November 2025 and accepted a resubmission on October 22, 2026.
When will the FDA decide on Biohaven’s Vyglxia?
Biohaven expects a decision in the first quarter of 2027, per the securities filing reported by BioPharma Dive. The FDA plans to convene an advisory committee first; no meeting date has been announced.
Did the Vyglxia resubmission receive priority review?
Nothing in the October 22, 2026 disclosure says so. The priority review designation often quoted with this program belongs to the original February 2025 filing cycle, which ended in a complete response letter.
What will Zai Lab use the $250 million placement for?
Primarily the continued global development of zocilurtatug pelitecan, its DLL3 targeting antibody drug conjugate, per the company’s release. The placement, led by TCGX, is expected to close on or about October 27, 2026.
How much does Medicare pay for Lucid’s EsoGuard test?
Lucid says it is being paid at the established clinical laboratory fee schedule rate of $1,938.01 per test, under PLA code 0114U, on claims submitted after its September 22, 2026 announcement.
When will the QIAGEN take private close?
EQT and QIAGEN target a close in mid 2027, subject to the formal offer process and a minimum acceptance of 50% plus one share. QIAGEN publishes full third quarter results on November 4, 2026 without a conference call.
When does ESMO 2026 take place?
The ESMO Congress runs October 23 to 27, 2026 in Madrid. Zentalis presents interim DENALI overall survival data in a rapid oral session on October 23, and AbbVie, Lilly, Incyte, Natera and others have presentation slates through the weekend.
Sources
Primary sources: US Department of the Treasury press release, “Treasury Issues Proposed Rule to Implement Comprehensive Outbound Investment National Security Act,” October 22, 2026; AstraZeneca press release on the Ultomiris IgAN accelerated approval, October 22, 2026 (carried by EuropaWire); Zai Lab private placement release, October 22, 2026 (Business Wire); Lucid Diagnostics release on EsoGuard Medicare payments and Series C placement, October 22, 2026 (PR Newswire); Labcorp release on the FDA and Charles River research collaboration, October 22, 2026 (PR Newswire); Mineralys Therapeutics release on Launch-HTN data at ASN Kidney Week, October 22, 2026 (GlobeNewswire); QIAGEN and EQT joint announcement, October 21, 2026.
Trade press and market coverage (attributed): BioPharma Dive on the Biohaven troriluzole acceptance (October 22, 2026, citing a Biohaven securities filing); Fierce Biotech on the Menarini Stemline and Georgiamune license, the NodThera IPO plan, and the Roche CEO’s Poseida comments (October 22, 2026); Fierce Biotech on China’s draft export control catalogue (October 16, 2026); Bloomberg and STAT News on the Treasury proposal’s China framing (October 22, 2026). Closing prices are settled exchange closes; percentage moves are our arithmetic.
